Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
18 October 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Dr Reddys Laboratories Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 2,385.40
Net Changes 4.05
Volume 333114
Prev Close 2,381.35
2,385.40 4.05 (0.17%)
Date: Oct 18,2017 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 2383 Div Yield (%) 1.01
Buy (Size) 0.00(×0) Eps(Rs) 58.33
Sell (Size) 0.00(×0) Book Value(Rs) 699.3088771
Buy Quantity 0 Market Cap(Rs.Cr) 39559.97
Sell Quantity 0 Face Value(Rs) 5
Today's High 2403.7 Market Lot 1
Today's Low 2376.55 AGM Date Jul
52-Week High 3394.95 Book Closure Date Jul
52-Week Low 1901.65 ISIN No. INE089A01023

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 44398828 26.78
Total of Promoter 44398828 26.78
Non Promoter (Institution) 71931988 43.38
Non Promoter (Non-Institution) 49471158 29.84
Total Non Promoter 121403146 73.22
Total Promoter & Non Promoter 165801974 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 165801974 100.00

Company News

17-Oct-2017  Dr. Reddy's Laboratories Limited - Press Release
Dr. Reddy's Laboratories Limited - Press Release

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 16, 2017, titled 'Dr. Reddy's to release Q2 FY18 results on October 31, 2017 Earnings call slated for October 31, 6.30 PM IST / 9.00 AM EDT'.
12-Oct-2017  Other announcement of Dr. Reddy's Laboratories Ltd
Other announcement of Dr. Reddy's Laboratories Ltd

This is to inform you that the Nomination, Governance & Compensation committee of the Board of Directors of the Company has allotted 7,987 equity shares of Rs.5/- each of the Company, fully paid up, on October 12, 2017, to Employees on exercise of their Stock Options.
12-Oct-2017  Dr. Reddy's Laboratories Limited - Allotment of Securities
Dr. Reddy's Laboratories Limited - Allotment of Securities

Dr. Reddy's Laboratories Limited has informed the Exchange regarding allotment of 7987 securities pursuant to ESOP/ESPS at its meeting held on October 12, 2017
06-Oct-2017  Dr Reddys Laboratories to conduct board meeting
Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 31 October 2017.
05-Oct-2017  Dr. Reddy's Laboratories Limited - Disclosure under SEBI Takeo...
Dr. Reddy's Laboratories Limited - Disclosure under SEBI Takeover Regulations

Dr. Reddy's Holdings Ltd has submitted to the Exchange, vide letter dated October 05, 2017 a copy of disclosure under Regulation 10(6) in respect of acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
03-Oct-2017  Dr Reddy's in pink of health after launching drug
Dr Reddy's in pink of health after launching drug

The announcement was made on Saturday, 30 September 2017.

Meanwhile, the S&P BSE Sensex was up 229.97 points, or 0.74% to 31,516.50.

On the BSE, 35,235 shares were traded in the counter so far, compared with average daily volumes of 74,637 shares in the past one quarter. The stock had hit a high of Rs 2,415 and a low of Rs 2,355 so far during the day. The stock had hit a 52-week high of Rs 3,394.95 on 28 October 2016. The stock had hit a 52-week low of Rs 1,901.65 on 11 August 2017.

The large-cap company has equity capital of Rs 82.94 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories announced the launch of Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent of Renvela (sevelamer carbonate) Tablets approved by the United States Food & Drug Administration (USFDA) in the US market. Renvela is a trademark of Genzyme Corporation.

The Renvela brand and generic has US sales of around $1.88 billion for the most recent twelve months ended in July 2017, according to IMS Health.

On a consolidated basis, Dr Reddy's Laboratories' net profit declined 56.6% to Rs 66.60 crore on 2.5% rise in net sales to Rs 3315.90 crore in Q1 June 2017 over Q1 June 2016.

Dr Reddy's Laboratories is an integrated global pharmaceutical company.

03-Oct-2017  Dr. Reddy's Laboratories Limited - Press Release
Dr. Reddy's Laboratories Limited - Press Release

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated September 29, 2017, titled 'Dr. Reddy's Laboratories announces the launch of Sevelamer Carbonate Tablets in the U.S. Market'.
29-Sep-2017  Other announcement of Dr. Reddy's Laboratories Ltd
Other announcement of Dr. Reddy's Laboratories Ltd

With reference to the earlier letter dated June 16, 2017 with regard to the audit of the Company's Formulation Srikakulam Plant (SEZ) Unit I, Andhra Pradesh, Dr Reddys Laboratories Ltd has now informed BSE that the Company have received an Establishment Inspection Report (EIR) from the US FDA, for the above- referred facility.
28-Sep-2017  Dr Reddys Laboratories receives EIR Report for Srikakulam Plan...
Dr Reddys Laboratories receives EIR Report for Srikakulam Plant (SEZ) Unit I

Dr Reddys Laboratories has received an Establishment Inspection Report (EIR) from the US FDA, for the Company's Formulation Srikakulam Plant (SEZ) Unit I, Andhra Pradesh.
28-Sep-2017  Dr Reddys Lab jumps after as Andhra formulation unit receives...
Dr Reddys Lab jumps after as Andhra formulation unit receives EIR

Meanwhile, the S&P BSE Sensex was up 65.22 points, or 0.21% to 31,225.03.

On the BSE, 77,000 shares were traded in the counter so far, compared with average daily volumes of 98,000 shares in the past one quarter. The stock had hit a high of Rs 2,409 and a low of Rs 2,276 so far during the day.

Dr Reddys Laboratories said it received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the company's formulation Srikakulam plant (SEZ) Unit I in Andhra Pradesh.

The company had in June 2017 announced that USFDA has completed the audit of the formulation Srikakulam plant (SEZ) Unit I on 16 June 2017 and had issued a Form 483 with one observation.

On a consolidated basis, Dr Reddys Laboratories' net profit declined 56.6% to Rs 66.60 crore on 2.5% rise in net sales to Rs 3315.90 crore in Q1 June 2017 over Q1 June 2016.

Dr Reddys Laboratories is an integrated global pharmaceutical company.

Incorporation Year 1984 
Registered Office 8-2-337 Road No 3,Banjara Hills,
,
Telangana-500034
Telephone 91-40-49002900 
Fax 91-40-49002999 
Chairman Satish Reddy
Managing Director NA
Company Secretary Sandeep Poddar 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,New York,NSE 
Registrar Big Share Services Pvt Ltd
3rd Flr 306 Rightwin,Amrutha Ville,Somajiguda,Hyderabad-500082 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS